Contact hypersensitivity (CHS) is a T cell–mediated skin inflammation induced by epicutaneous exposure to haptens in sensitized individuals. We have previously reported that CHS to dinitrofluorobenzene in mice is mediated by major histocompatibility complex (MHC) class I–restricted CD8+ T cells. In this study, we show that CD8+ T cells mediate the skin inflammation through their cytotoxic activity. The contribution of specific cytotoxic T lymphocytes (CTLs) to the CHS reaction was examined both in vivo and in vitro, using mice deficient in perforin and/or Fas/Fas ligand (FasL) pathways involved in cytotoxicity. Mice double deficient in perforin and FasL were able to develop hapten-specific CD8+ T cells in the lymphoid organs but did not show CHS reaction. However, they did not generate hapten-specific CTLs, demonstrating that the CHS reaction is dependent on cytotoxic activity. In contrast, Fas-deficient lpr mice, FasL-deficient gld mice, and perforin-deficient mice developed a normal CHS reaction and were able to generate hapten-specific CTLs, suggesting that CHS requires either the Fas/FasL or the perforin pathway. This was confirmed by in vitro studies showing that the hapten-specific CTL activity was exclusively mediated by MHC class I–restricted CD8+ T cells which could use either the perforin or the Fas/FasL pathway for their lytic activity. Thus, cytotoxic CD8+ T cells, commonly implicated in the host defence against tumors and viral infections, could also mediate harmful delayed-type hypersensitivity reactions.
Skip Nav Destination
Article navigation
1 March 1999
Article|
March 01 1999
Cytotoxicity Is Mandatory for CD8+ T Cell–mediated Contact Hypersensitivity
Jeanne Kehren,
Jeanne Kehren
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Cyril Desvignes,
Cyril Desvignes
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Maya Krasteva,
Maya Krasteva
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Marie-Thérèse Ducluzeau,
Marie-Thérèse Ducluzeau
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Olga Assossou,
Olga Assossou
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Françoise Horand,
Françoise Horand
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Michael Hahne,
Michael Hahne
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
David Kägi,
David Kägi
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Dominique Kaiserlian,
Dominique Kaiserlian
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Jean-François Nicolas
Jean-François Nicolas
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Search for other works by this author on:
Jeanne Kehren
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Cyril Desvignes
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Maya Krasteva
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Marie-Thérèse Ducluzeau
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Olga Assossou
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Françoise Horand
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Michael Hahne
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
David Kägi
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Dominique Kaiserlian
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Jean-François Nicolas
From the *Institut National de la Santé et de la Recherche Médicale (INSERM) U503, Faculté Laennec, F-69372 Lyon Cedex 08, France; ‡INSERM U404, F-69365 Lyon Cedex 07, France; the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, France; the ‖Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; and the ¶Department of Clinical Immunology, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite, France
Address correspondence to Jean-François Nicolas, ImmunoDermatology, INSERM U503, Faculté Laennec, F-69372 Lyon Cedex 08, France. Fax: 33-478-778-770; E-mail: [email protected]
Received:
June 05 1998
Revision Received:
January 11 1999
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1999
J Exp Med (1999) 189 (5): 779–786.
Article history
Received:
June 05 1998
Revision Received:
January 11 1999
Citation
Jeanne Kehren, Cyril Desvignes, Maya Krasteva, Marie-Thérèse Ducluzeau, Olga Assossou, Françoise Horand, Michael Hahne, David Kägi, Dominique Kaiserlian, Jean-François Nicolas; Cytotoxicity Is Mandatory for CD8+ T Cell–mediated Contact Hypersensitivity . J Exp Med 1 March 1999; 189 (5): 779–786. doi: https://doi.org/10.1084/jem.189.5.779
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement